Good morning, everyone. We're here today to discuss a strategic partnership that will fundamentally reshape the animal health market in Zambia. This isn't just about distribution; it's about capturing a national market and building a lasting competitive advantage. We've identified a unique opportunity for Zikomed to lead this transformation. Let's dive into how we can achieve this together.
This partnership offers Zikomed a unique opportunity to dominate a rapidly expanding market. Zambia's cattle population is set to grow by 45% to 7.4 million by 2027, creating massive demand for animal health products. Agriserve Agro is Zambia's only local manufacturer, with a ZAMRA license and significant production capacity, giving us an unparalleled competitive edge. Our proposed commercial model offers Zikomed a blended average margin of around 17%, with a clear path to over $1 million in annual gross profit. This isn't just a supply agreement; it's a long-term strategic collaboration to build a dominant national brand and position Zambia as a regional manufacturing hub. Now, let's look at the market dynamics driving this opportunity.
The Zambian animal health market is at a critical inflection point, presenting a once-in-a-generation opportunity. Government policy aims to increase the cattle population by 45% to 7.4 million by 2027, directly fueling demand for our products. The regional supply vacuum, caused by South Africa's FMD crisis and Zambia's import suspension, creates an urgent need for local production. And with East Coast Fever costing the region $168 million annually, effective and affordable tick control is an economic imperative. This convergence of factors makes the timing for our partnership absolutely perfect. And Agriserve Agro is uniquely positioned to capitalize on this.
Agriserve Agro is not just a manufacturer; we are Zambia's only local, ZAMRA-licensed animal health pharmaceutical producer. Our ZAMRA manufacturing license, PHAR/MAN-25-0069, is valid until October 2027, solidifying our unique position. We have a robust production capacity of 60,000 liters per month, capable of serving both smallholder and commercial markets. Our leadership team, led by myself and Dr. Mutinta Mulokota, ensures GMP and ZAMRA compliance, guaranteeing quality and reliability. This local manufacturing capability is our competitive moat, and it's what makes this partnership so powerful. And our product range is ready for national scale.
Our Alpha Range is a complete portfolio of six ZAMRA-approved products, covering three distinct chemistry platforms. This comprehensive range, including innovative dual-action formulations, addresses critical pest control needs and offers solutions for resistance management. All products are approved for general sale, meaning no prescription is required, simplifying distribution and access. Our flexible packaging options, from 20ml to 200L, cater to the diverse needs of both smallholder and commercial farmers. This complete and approved product line is the engine of our proposed partnership. Next, we'll examine how this range gives us a significant advantage in the competitive landscape.
Our Alpha Range isn't just another product line; it's a strategic advantage in the Zambian market. We offer equivalent efficacy to imported brands, but at a significantly lower cost, ranging from 5% to a remarkable 48% more affordable. This pricing power comes from our local manufacturing, eliminating import lead times and currency risks. We can also adapt quickly to market needs with flexible repackaging and local labeling. This means Zikomed gains a competitive edge, offering superior value to customers while ensuring a stable, agile supply chain. This competitive moat is just the beginning; let's look at how we're expanding this advantage.
Building on our competitive edge, the Alpha Range is a dynamic platform, not a static offering. We're launching three new products in 2026, automatically expanding Zikomed's portfolio and market reach. Our immediate pipeline includes Alphatraz 125, Alphacyp Dip, and Alphatic Grease, all in various stages of development or ready for stock. Beyond these, our long-term roadmap is ambitious, moving from ectoparasite control to internal and oral treatments, and eventually to a full spectrum of injectable veterinary medicines. This continuous innovation ensures Zikomed will always have a fresh, expanding portfolio to offer. So, how does Zikomed fit into this growth story?
This slide really highlights the synergy between our two companies: Zikomed has the reach, and Agriserve has the product. Together, we can truly own the value chain. Zikomed brings critical infrastructure like GDP warehousing, national logistics, and a strong commercial sales team with deep regulatory expertise. Agriserve, on the other hand, provides local manufacturing, a registered product portfolio, and significant production capacity. This partnership creates a vertically integrated solution from manufacturing to the farmer's gate, a model with no equivalent competitor in Zambia. We also see a significant Phase 2 opportunity in contract packaging and bulk import, opening up additional shared revenue streams. Now, let's dive into the commercial framework that underpins this powerful partnership.
Our commercial model is designed for mutual profitability, ensuring Zikomed's success is directly tied to the market dynamics of each product. We've established a tiered margin framework, ranging from 12% to 20%, aligning profitability with product categories. For instance, our high-margin innovator products like Alphatic Double Action offer a 20% margin, reflecting their strong gross profit headroom. Even our volume-driven products, like Alphatraz 125, provide a solid 12% margin for maximum market penetration. This structure ensures Zikomed benefits from both premium and high-volume sales, all while offering end-users a significant price advantage of 5% to 48% compared to imported competitors. This clear profitability leads us directly to the exciting sales potential we project.
This slide clearly illustrates the significant financial opportunity for Zikomed, with a clear path to over $1 million in annual gross profit. Even with conservative projections at 30% capacity utilization, we're looking at $677,000 in Zikomed gross profit. At a moderate 50% capacity, that figure jumps to $1.1 million. We also have 28,400 liters of initial stock, valued at approximately ZMW 12.7 million retail, ready for immediate market deployment. These are conservative numbers, demonstrating a robust and achievable revenue stream for Zikomed from year one. Next, we'll discuss how we'll build the Alpha brand together through targeted marketing and demand generation.
Now, to truly capitalize on that sales potential, we need a robust marketing and demand generation strategy. This isn't just about selling product; it's about building the Alpha brand as the undisputed leader in animal health. We've developed a multi-channel approach, hitting every touchpoint from professional vets to local farmers. Our strategy includes direct engagement with veterinary officers and co-op partnerships, ensuring professional endorsement and broad reach. We'll also connect directly with farmers through 'Dip Days' and training workshops, demonstrating proper usage and building trust. This comprehensive strategy ensures strong sell-through and solidifies our market position.
Beyond the commercial upside, our partnership delivers significant ESG impact and leverages local manufacturing advantages. This isn't just good for business; it's good for Zambia. As a female-owned and led business, Agriserve Agro actively empowers women across the agricultural value chain, from mentorship to targeted extension services. Our local manufacturing shifts value capture from imports to the Zambian economy, creating high-value technical jobs in critical sectors like pharmaceutical manufacturing and quality control. We're also implementing a circular economy model with a return-for-credit packaging system, reducing waste and lowering costs. This commitment to ESG strengthens our competitive moat and resonates deeply with our customers. It also sets the stage for our broader vision.
Looking ahead, our ambition extends beyond national leadership to becoming a regional exporter. We see Zambia as a strategic hub for veterinary pharmaceutical manufacturing across Southern Africa. Leveraging the SADC regulatory framework, we can streamline product registration and significantly reduce barriers to entry in key markets like Zimbabwe, Malawi, Botswana, and Namibia. Our future manufacturing campus will expand production capacity to support these export volumes and new product lines, including injectables. This expansion includes a centralized distribution center, an R&D laboratory for accelerated innovation, and a training academy. This strategic regional expansion will cement our position as a dominant force in the African animal health market.
Our vision for regional export, as we just discussed, hinges on a robust execution strategy. This 12-month roadmap details how we'll move from agreement to significant scale, ensuring operational stability and rapid market penetration. In the first three months, we'll finalize our distribution agreement and allocate 28,400 liters of launch inventory. This initial phase includes comprehensive sales team training for your reps and listing in the top 50 pharmacies and agro-dealers. Months four through six focus on acceleration, with a national "Dip Day" campaign and regional roadshows, alongside the launch of Alphatraz 125, our volume driver. By months seven to twelve, we'll be scaling rapidly, introducing new products like Alphacyp Dip and Alphatic Grease, expanding into non-traditional retail, and optimizing inventory based on real-time data. This structured approach ensures we maximize market impact and prepare for future regional expansion. Now, let's look at the immediate actions needed to kick this off.
Building on that clear roadmap, these are the immediate next steps to formalize our partnership and begin operations. First, we need to review and sign the National Distribution Agreement, confirming the tiered margin structure and exclusivity. This is crucial for mutual value creation. Second, we'll secure the initial inventory by issuing a purchase order for the 28,400 liters of stock, valued at approximately ZMW 12.7 million, ensuring we're ready for market. Third, we'll establish a joint working group to finalize the marketing calendar, sales training, and logistics. This collaborative effort will ensure a seamless national rollout, supported by initial radio and digital campaigns, targeting full market activation by April 1, 2026. This is how we seize this significant opportunity together. And with that, I'd like to thank you for your time and attention.
Thank you for your time today. We believe this partnership represents a significant commercial opportunity for both Agriserve Agro and Zikomed. We're confident that together, we can build the future of animal health in Zambia and beyond. My contact information is here, and I encourage you to explore our full product portfolio online. We look forward to working closely with you.
Confidential — Agriserve Agro & Zikomed Partnership Proposal